An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and thymosin beta-4. The panel turned down emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for expanded access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how regulators view compounded peptide therapies, which have drawn growing interest from patients seeking alternatives to conventional drugs. Researchers say peptide treatments could reshape approaches to difficult infections, though concerns about quality persist. The committee's endorsement of four peptides paves the way for more widespread prescribing, even as critics warn of short-term evidence. Industry analysts note that peptide-focused companies may see heightened investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on certain peptide candidates.